Suvratoxumab Biosimilar – Anti-alpha toxin mAb – Research Grade from ProteoGenix; catalogue PX-TA1460; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Suvratoxumab Biosimilar, also known as Anti-alpha toxin mAb, is a monoclonal antibody that targets the alpha toxin produced by the bacterium Staphylococcus aureus. This biosimilar is a research grade antibody that has shown promising results in pre-clinical studies and has the potential to be developed as a therapeutic treatment for Staphylococcus aureus infections.
Suvratoxumab Biosimilar is a recombinant humanized monoclonal antibody that is produced by genetic engineering techniques. It is composed of two heavy chains and two light chains, each containing variable and constant regions. The variable regions of the antibody are responsible for binding to the alpha toxin, while the constant regions provide stability and effector functions.
The structure of Suvratoxumab Biosimilar is similar to that of the natural human antibody, making it less likely to cause an immune response in patients. This also allows for better targeting and binding to the alpha toxin, increasing the effectiveness of the antibody.
Suvratoxumab Biosimilar works by binding to the alpha toxin produced by Staphylococcus aureus. This binding prevents the toxin from interacting with its target cells, thereby neutralizing its harmful effects. The antibody also triggers an immune response, leading to the destruction of the bacteria and clearance of the infection.
In addition to its neutralizing activity, Suvratoxumab Biosimilar also has effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These mechanisms further enhance the antibody’s ability to eliminate the bacteria and its toxin.
Suvratoxumab Biosimilar has potential applications in the treatment of Staphylococcus aureus infections. This bacterium is responsible for a wide range of diseases, from skin and soft tissue infections to life-threatening conditions such as pneumonia, sepsis, and endocarditis.
The use of Suvratoxumab Biosimilar as a therapeutic treatment can help in reducing the severity and duration of these infections. It can also prevent the development of antibiotic resistance, which is a major concern in the treatment of Staphylococcus aureus infections.
Suvratoxumab Biosimilar can be used to treat skin and soft tissue infections caused by Staphylococcus aureus, such as impetigo, cellulitis, and abscesses. These infections are commonly treated with antibiotics, but with the increasing prevalence of antibiotic-resistant strains, the use of an alternative treatment like Suvratoxumab Biosimilar can be beneficial.
Staphylococcus aureus is one of the leading causes of pneumonia, especially in hospitalized patients. Suvratoxumab Biosimilar can be used as an adjunct treatment to antibiotics in severe cases of pneumonia, as it can help in reducing the bacterial load and improving patient outcomes.
Staphylococcus aureus infections can also lead to life-threatening conditions such as sepsis and endocarditis. Suvratoxumab Biosimilar can be used as a targeted therapy to neutralize the alpha toxin and prevent the progression of these infections.
In conclusion, Suvratoxumab Biosimilar is a promising antibody that targets the alpha toxin produced by Staphylococcus aureus. Its unique structure and activity make it an effective treatment option for a wide range of Staphylococcus aureus infections. Further clinical studies are needed to fully evaluate the efficacy and safety of this biosimilar, but it has the potential to be a valuable addition to the treatment of these infections.
ProteoGenix catalogue number PX-TA1460. For research use only.
Target: Suvratoxumab Biosimilar – Anti-alpha toxin mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Suvratoxumab Biosimilar – Anti-alpha toxin mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
